ABBV

SEC source: 0001179110-20-002868 · edgar.xml · nonDerivative · entry 1

Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,784

SEC source: 0001179110-20-002138 · edgar.xml · nonDerivative · entry 5

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 523,561

SEC source: 0001179110-20-002128 · edgar.xml · derivative · entry 6

Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,099

Underlying: Common Stock · 49,099 shares

Expires 2030-02-19

F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023.

SEC source: 0001179110-20-002128 · edgar.xml · nonDerivative · entry 4

Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,487

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002128 · edgar.xml · nonDerivative · entry 3

Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,311

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002128 · edgar.xml · nonDerivative · entry 2

Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,341

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002128 · edgar.xml · nonDerivative · entry 1

Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,431

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002129 · edgar.xml · derivative · entry 5

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,566

Underlying: Common Stock · 114,566 shares

Expires 2030-02-19

F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,189 on February 20, 2021, 38,189 on February 20, 2022, and 38,188 on February 20, 2023.

SEC source: 0001179110-20-002129 · edgar.xml · nonDerivative · entry 4

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,452

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002129 · edgar.xml · nonDerivative · entry 3

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,973

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002129 · edgar.xml · nonDerivative · entry 2

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,408

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002129 · edgar.xml · nonDerivative · entry 1

SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,419

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002130 · edgar.xml · derivative · entry 5

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,566

Underlying: Common Stock · 114,566 shares

Expires 2030-02-19

F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,189 on February 20, 2021, 38,189 on February 20, 2022, and 38,188 on February 20, 2023.

SEC source: 0001179110-20-002130 · edgar.xml · nonDerivative · entry 4

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,646

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002130 · edgar.xml · nonDerivative · entry 3

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 229,510

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002130 · edgar.xml · nonDerivative · entry 2

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,031

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002130 · edgar.xml · nonDerivative · entry 1

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,042

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002131 · edgar.xml · derivative · entry 7

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,649

Underlying: Common Stock · 73,649 shares

Expires 2030-02-19

F7 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,550 on February 20, 2021, 24,550 on February 20, 2022, and 24,549 on February 20, 2023.

SEC source: 0001179110-20-002131 · edgar.xml · nonDerivative · entry 4

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,209

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002131 · edgar.xml · nonDerivative · entry 3

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,641

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002131 · edgar.xml · nonDerivative · entry 2

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,362

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002131 · edgar.xml · nonDerivative · entry 1

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,192

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002132 · edgar.xml · derivative · entry 5

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,559

Underlying: Common Stock · 78,559 shares

Expires 2030-02-19

F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,187 on February 20, 2021, 26,186 on February 20, 2022, and 26,186 on February 20, 2023.

SEC source: 0001179110-20-002132 · edgar.xml · nonDerivative · entry 4

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,907

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002132 · edgar.xml · nonDerivative · entry 3

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,908

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002132 · edgar.xml · nonDerivative · entry 2

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,804

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002132 · edgar.xml · nonDerivative · entry 1

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,964

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002133 · edgar.xml · derivative · entry 5

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,382

Underlying: Common Stock · 106,382 shares

Expires 2030-02-19

F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 35,461 on February 20, 2021, 35,461 on February 20, 2022, and 35,460 on February 20, 2023.

SEC source: 0001179110-20-002133 · edgar.xml · nonDerivative · entry 4

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,708

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002133 · edgar.xml · nonDerivative · entry 3

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,849

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002133 · edgar.xml · nonDerivative · entry 2

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,364

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002133 · edgar.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,654

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002134 · edgar.xml · derivative · entry 5

Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,193

Underlying: Common Stock · 62,193 shares

Expires 2030-02-19

F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,731 on February 20, 2021, 20,731 on February 20, 2022, and 20,731 on February 20, 2023.

SEC source: 0001179110-20-002134 · edgar.xml · nonDerivative · entry 4

Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,120

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002134 · edgar.xml · nonDerivative · entry 3

Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,588

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002134 · edgar.xml · nonDerivative · entry 2

Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,349

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002134 · edgar.xml · nonDerivative · entry 1

Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,069

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002135 · edgar.xml · derivative · entry 7

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,563

Underlying: Common Stock · 96,563 shares

Expires 2030-02-19

F7 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,188 on February 20, 2021, 32,188 on February 20, 2022, and 32,187 on February 20, 2023.

SEC source: 0001179110-20-002135 · edgar.xml · nonDerivative · entry 4

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,544

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002135 · edgar.xml · nonDerivative · entry 3

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,572

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002135 · edgar.xml · nonDerivative · entry 2

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,017

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002135 · edgar.xml · nonDerivative · entry 1

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,287

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002136 · edgar.xml · derivative · entry 2

Donoghoe Nicholas · CIK 0001762951 · SVP, Enterprise Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,013

Underlying: Common Stock · 72,013 shares

Expires 2030-02-19

F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,005 on February 20, 2021, 24,004 on February 20, 2022, and 24,004 on February 20, 2023.

SEC source: 0001179110-20-002136 · edgar.xml · nonDerivative · entry 1

Donoghoe Nicholas · CIK 0001762951 · SVP, Enterprise Innovation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,504

F1 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002137 · edgar.xml · derivative · entry 6

ALBAN CARLOS · CIK 0001474632 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,566

Underlying: Common Stock · 114,566 shares

Expires 2030-02-19

F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,189 on February 20, 2021, 38,189 on February 20, 2022, and 38,188 on February 20, 2023.

SEC source: 0001179110-20-002137 · edgar.xml · nonDerivative · entry 4

ALBAN CARLOS · CIK 0001474632 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,316

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002137 · edgar.xml · nonDerivative · entry 3

ALBAN CARLOS · CIK 0001474632 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,191

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002137 · edgar.xml · nonDerivative · entry 2

ALBAN CARLOS · CIK 0001474632 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,977

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002137 · edgar.xml · nonDerivative · entry 1

ALBAN CARLOS · CIK 0001474632 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,637

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002138 · edgar.xml · derivative · entry 9

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 229,132

Underlying: Common Stock · 229,132 shares

Expires 2030-02-19

F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 76,378 on February 20, 2021, 76,377 on February 20, 2022, and 76,377 on February 20, 2023.